You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIA

    Project Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias

    SBC: Path Biotech, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Next-generation nanomedicine for acute ischemic stroke

    SBC: Nanomuse, LLC            Topic: NINDS

    ABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups

    SBC: JP LABORATORIES INC            Topic: 300

    Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.

    SBC: Zena Therapeutics Inc.            Topic: NIDA

    Opioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 104

    Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis

    SBC: Prokaryotics, Inc.            Topic: NIAID

    Widespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Recombinant E-NTPDase for shock

    SBC: Purine Pharmaceuticals Inc.            Topic: 300

    SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Large Form Factor Scintillators for Nuclear Battlefield Operations

    SBC: N.P. PHOTONICS, INC.            Topic: DTRA22D002

    The current state-of-the-art radiation detection materials have different drawbacks limiting their applications in the next-generation mobile radiation detection system. NP Photonics proposes to develop a novel scintillating glass that can be used to make large form-factor scintillators for nuclear battlefield operations. The proposed scintillating glass has the advantages of low cost, short decay ...

    STTR Phase I 2023 Department of DefenseDefense Threat Reduction Agency
US Flag An Official Website of the United States Government